Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05812157
Other study ID # IDRCB : 2022-A00135-38
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date October 2, 2023
Est. completion date December 1, 2026

Study information

Verified date October 2023
Source Centre Hospitalier Universitaire de Nimes
Contact Cédric LUKAS, Professor
Phone +334 67 33 87 10
Email c-lukas@chu-montpellier.fr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Fiber is the main source of energy for colonic bacteria and its consumption favorably modifies the composition of the microbiota in only a few days. Their fermentation in the colon releases short-chain fatty acids (SCFAs). Clostridiales contain many strains producing SCFAs. These SCFAs can restore the intestinal barrier and promote certain anti-inflammatory cells, including regulatory T cells (Tregs), which are essential to the mechanisms in tolerance of the self. Fibers could therefore correct the intestinal abnormalities present in patients with axial spondyloarthritis (AxSpA) and aggravated by anti-IL-17 drugs and thus improve the therapeutic response to these treatments. The hypothesis is that dietary fiber will correct the dysbiosis in AxSpA patients and increase the release of SCFAs, which favorably modulate the immune response and improve AxSpA.


Description:

Axial spondyloarthritis (AxSpA) is the second most common chronic inflammatory rheumatic disease, which develops preferentially in young subjects and results in a significant impairment of quality of life, particularly due to painful symptoms. The importance of the digestive system has long been recognized, since this disease is considered to be part of a larger group of diseases including Crohn's disease and ulcerative colitis because of their frequent association in the same patient, and because leaky gut disorders and alterations of the intestinal microbiota (dysbiosis) have been described in these patients. These abnormalities may stimulate the immune system and therefore be involved in inflammatory processes (especially Th17). The available treatments are based on non-steroidal anti-inflammatory drugs, and in the event of failure or intolerance, biomedicines targeting TNF can be used. Therapeutic monoclonal antibodies against IL-17 have recently enriched the therapeutic arsenal. Although most anti-TNF agents have a beneficial effect on the rheumatologic and digestive aspects of these diseases, anti-IL-17 agents are not expected to be effective in inflammatory bowel diseases. Indeed, a deleterious role of anti-IL-17 on the intestinal microbiota has even been demonstrated, which could result in a reduction of the systemic anti-inflammatory effect expected from these molecules, and consequently of the clinical benefit felt by the patient. In fact, anti-IL-17s lead to a significant decrease in Clostridiales, bacteria that participate in intestinal homeostasis. Fiber is the main source of energy for colonic bacteria and its consumption favorably modifies the composition of the microbiota in just a few days. Their fermentation in the colon releases short-chain fatty acids (SCFAs). Clostridiales contain many strains producing SCFAs. These SCFAs can restore the intestinal barrier and promote certain anti-inflammatory cells, including regulatory T cells (Tregs), which are essential to the mechanisms in tolerance of the self. Fibers could therefore correct the intestinal abnormalities present in AxSpA patients and aggravated by anti-IL-17 drugs and thus improve the therapeutic response to these treatments. The hypothesis is therefore that dietary fiber will correct the dysbiosis in AxSpA patients and increase the release of SCFAs, which favorably modulate the immune response and thus improve AxSpA.


Recruitment information / eligibility

Status Recruiting
Enrollment 36
Est. completion date December 1, 2026
Est. primary completion date December 1, 2026
Accepts healthy volunteers No
Gender All
Age group 18 Years to 90 Years
Eligibility Inclusion criteria: - Patients with spondyloarthritis meeting the ASAS criteria - Patient considered by the treating rheumatologist for anti-IL-17 biomedication - Patients aged between 18 and 90 years of age - Patients who are affiliated to a French social security system or beneficiaries of such a system - Patients with no desire to become pregnant during the study period (Effective contraception for women of childbearing age during the study period (surgical sterilization, hormonal contraceptives, barrier method, intrauterine device)) Exclusion Criteria: - Lack of written informed consent after a time of reflection - Patients participating in other therapeutic research or having participated in research for which the exclusion period has not ended - Patient under court protection, guardianship or curatorship. - Patient unable to give consent. - Pregnant or breastfeeding woman - Patients with digestive disorders for which a chronic inflammatory bowel disease has not been excluded - Patients with fructose intolerance or glucose or galactose malabsorption - Patients with known intolerance to inulin or maltodextrin

Study Design


Intervention

Dietary Supplement:
Daily dietary supplementation with Fibruline
Supplementation with 12 grams per day of Fibruline reconstituted with 60mL of water, once a day
Drug:
Anti-IL-17 therapy
Patients in both groups will be on anti-IL-17 therapy

Locations

Country Name City State
France Montpellier University Hospital Montpellier Hérault
France Nîmes University Hospital Nîmes Gard
France Tours Regional University Hospital (Bretonneau) Tours Indre-et-Loire

Sponsors (1)

Lead Sponsor Collaborator
Centre Hospitalier Universitaire de Nimes

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Clostridial changes in the Experimental group Patients will receive fiber supplementation with inulin (Fibruline® Instant, Fagron laboratory) at a rate of 12 grams of powder per day reconstituted with approximately 60mL of water and consumed in one intake per day. To confirm the efficacy of treatment, the percentage of patients with a >10% decrease in Clostriadiales in their stools at 3 months after initiation of anti-IL-17 will be recorded. This percentage will be based on the distribution of bacteria analyzed by 16S RNA sequencing. Week 0
Primary Clostridial changes in Controls Patients will receive a placebo consisting of Maltodextrin (Fagron laboratories), packaged in jars identical to those used for inulin, with a volumetric equivalent, an energy contribution and very similar color. Patients will consume 12 grams of powder per day reconstituted with approximately 60mL of water and consumed in one intake per day. The percentage of patients with a >10% decrease in Clostriadiales in their stools at 3 months after initiation of anti-IL-17 will be recorded. This percentage will be based on the distribution of bacteria analyzed by 16S RNA sequencing. Week 0
Primary Clostridial changes in the Experimental group Patients will receive fiber supplementation with inulin (Fibruline® Instant, Fagron laboratory) at a rate of 12 grams of powder per day reconstituted with approximately 60mL of water and consumed in one intake per day. To confirm the efficacy of treatment, the percentage of patients with a >10% decrease in Clostriadiales in their stools at 3 months after initiation of anti-IL-17 will be recorded. This percentage will be based on the distribution of bacteria analyzed by 16S RNA sequencing. Week 12
Primary Clostridial changes in Controls Patients will receive a placebo consisting of Maltodextrin (Fagron laboratories), packaged in jars identical to those used for inulin, with a volumetric equivalent, an energy contribution and very similar color. Patients will consume 12 grams of powder per day reconstituted with approximately 60mL of water and consumed in one intake per day. The percentage of patients with a >10% decrease in Clostriadiales in their stools at 3 months after initiation of anti-IL-17 will be recorded. This percentage will be based on the distribution of bacteria analyzed by 16S RNA sequencing. Week 12
Secondary Effect of fiber supplementation on clinical therapeutic response in the experimental group: Delta BASDAI Clinical response rates observed in patients treated with anti-IL-17 with fiber supplementation will be recorded as a percentage.
The BASDAI (Bath Ankylosing Spondylitis Disease Activity Index) will be used to measure the percentage of patients responding positively to treatment.
Week 0
Secondary Effect of fiber supplementation on clinical therapeutic response in the experimental group: Delta BASDAI Clinical response rates observed at 3 months in patients treated with anti-IL-17 with fiber supplementation will be recorded as a percentage.
The BASDAI (Bath Ankylosing Spondylitis Disease Activity Index) will be used to measure the percentage of patients responding positively to treatment.
Week 12
Secondary Effect of fiber supplementation on clinical therapeutic response in the experimental group: ASAS20 Clinical response rates observed in patients treated with anti-IL-17 with fiber supplementation will be recorded as a percentage.
The ASAS20 will be used to measure the percentage of patients responding positively to treatment. This tool was developed by the Assessment of SpondylArthritis international Society (ASAS). The ASAS Response Criteria (ASAS 20) is defined as an improvement in at least 20% and an absolute improvement in at least 10 units on a 0-100 scale in at least three of the following domains: Patient global assessment, Pain assessment, Function, and Inflammation (last 2 questions of BASDAI).
Week 0
Secondary Effect of fiber supplementation on clinical therapeutic response in the experimental group: ASAS20 Clinical response rates observed at 3 months in patients treated with anti-IL-17 with fiber supplementation will be recorded as a percentage.
The ASAS20 will be used to measure the percentage of patients responding positively to treatment. This tool was developed by the Assessment of SpondylArthritis international Society (ASAS). The ASAS Response Criteria (ASAS 20) is defined as an improvement in at least 20% and an absolute improvement in at least 10 units on a 0-100 scale in at least three of the following domains: Patient global assessment, Pain assessment, Function, and Inflammation (last 2 questions of BASDAI).
Week 12
Secondary Effect of fiber supplementation on clinical therapeutic response in the experimental group: ASAS40 Clinical response rates observed in patients treated with anti-IL-17 with fiber supplementation will be recorded as a percentage.
The ASAS40 will be used to measure the percentage of patients responding positively to treatment. This tool was developed by the Assessment of SpondylArthritis international Society (ASAS). The ASAS Response Criteria (ASAS 40) is defined as an improvement in at least 40% and an absolute improvement in at least 10 units on a 0-100 scale in at least three of the following domains: Patient global assessment, Pain assessment, Function, and Inflammation (last 2 questions of BASDAI).
Week 0
Secondary Effect of fiber supplementation on clinical therapeutic response in the experimental group: ASAS40 Clinical response rates observed at 3 months in patients treated with anti-IL-17 with fiber supplementation will be recorded as a percentage.
The ASAS40 will be used to measure the percentage of patients responding positively to treatment. This tool was developed by the Assessment of SpondylArthritis international Society (ASAS). The ASAS Response Criteria (ASAS 40) is defined as an improvement in at least 40% and an absolute improvement in at least 10 units on a 0-100 scale in at least three of the following domains: Patient global assessment, Pain assessment, Function, and Inflammation (last 2 questions of BASDAI).
Week 12
Secondary Effect of fiber supplementation on clinical therapeutic response in the experimental group: ASDAS Clinical response rates observed at 3 months in patients treated with anti-IL-17 with fiber supplementation will be recorded as a percentage.
The ASDAS (Ankylosing Spondylitis Disease Activity Score) will be used to measure the percentage of patients responding positively to treatment. This tool is an index to assess disease activity in Ankylosing Spondylitis. The preferred score uses CRP (C-reactive protein) rather than ESR (erythrocyte sedimentation rate).
Week 0
Secondary Effect of fiber supplementation on clinical therapeutic response in the experimental group: ASDAS Clinical response rates observed at 3 months in patients treated with anti-IL-17 with fiber supplementation will be recorded as a percentage.
The ASDAS (Ankylosing Spondylitis Disease Activity Score) will be used to measure the percentage of patients responding positively to treatment. This tool is an index to assess disease activity in Ankylosing Spondylitis. The preferred score uses CRP (C-reactive protein) rather than ESR (erythrocyte sedimentation rate).
Week 12
Secondary Effect of fiber supplementation on clinical therapeutic response: GIQLI Clinical response rates in patients treated with anti-IL-17 with fiber supplementation will be recorded as a percentage.
Digestive symptoms will be assessed using the Gastrointestinal Quality of Life Index (GIQLI) questionnaire at Week 0 and Week 12. The GIQLI is a measure of the subjective perception of well-being by a patient, which may vary unexpectedly between diagnostic groups. The GIQLI was initiated in Germany and includes 36 items asking about symptoms, physical status, emotions, social dysfunction, and effects of medical treatment. The Questions cover the following 5 dimensions : symptoms, physical condition, emotions, social integration and medical treatment.
Week 0
Secondary Effect of fiber supplmentation on clinical therapeutic response: GIQLI Clinical response rates observed at 3 months in patients treated with anti-IL-17 with fiber supplementation will be recorded as a percentage.
Digestive symptoms will be assessed using the Gastrointestinal Quality of Life Index (GIQLI) questionnaire at Week 0 and Week 12. The GIQLI is a measure of the subjective perception of well-being by a patient, which may vary unexpectedly between diagnostic groups. The GIQLI was initiated in Germany and includes 36 items asking about symptoms, physical status, emotions, social dysfunction, and effects of medical treatment. The Questions cover the following 5 dimensions : symptoms, physical condition, emotions, social integration and medical treatment.
Week 12
Secondary Effect at 12 weeks of placebo on clinical therapeutic response: Delta BASDAI Clinical response rates observed in patients treated with anti-IL-17 without fiber supplementation will be recorded as a percentage.
The BASDAI (Bath Ankylosing Spondylitis Disease Activity Index) will be used to measure the percentage of patients responding positively to treatment.
Week 0
Secondary Effect at 12 weeks of placebo on clinical therapeutic response: Delta BASDAI Clinical response rates observed at 3 months in patients treated with anti-IL-17 without fiber supplementation will be recorded as a percentage.
The BASDAI (Bath Ankylosing Spondylitis Disease Activity Index) will be used to measure the percentage of patients responding positively to treatment.
Week 12
Secondary Effect at 12 weeks of placebo on clinical therapeutic response: ASA20 Clinical response rates observed in patients treated with anti-IL-17 without fiber supplementation will be recorded as a percentage.
The ASAS20 will be used to measure the percentage of patients responding positively to treatment.This tool was developed by the Assessment of SpondylArthritis international Society (ASAS). The ASAS Response Criteria (ASAS 20) is defined as an improvement in at least 20% and an absolute improvement in at least 10 units on a 0-100 scale in at least three of the following domains: Patient global assessment, Pain assessment, Function, and Inflammation (last 2 questions of BASDAI).
Week 0
Secondary Effect at 12 weeks of placebo on clinical therapeutic response: ASA20 Clinical response rates observed at 3 months in patients treated with anti-IL-17 without fiber supplementation will be recorded as a percentage.
The ASAS20 will be used to measure the percentage of patients responding positively to treatment.This tool was developed by the Assessment of SpondylArthritis international Society (ASAS). The ASAS Response Criteria (ASAS 20) is defined as an improvement in at least 20% and an absolute improvement in at least 10 units on a 0-100 scale in at least three of the following domains: Patient global assessment, Pain assessment, Function, and Inflammation (last 2 questions of BASDAI).
Week 12
Secondary Effect at 12 weeks of placebo on clinical therapeutic response: ASA40 Clinical response rates observed in patients treated with anti-IL-17 without fiber supplementation will be recorded as a percentage.
The ASAS40 will be used to measure the percentage of patients responding positively to treatment.This tool was developed by the Assessment of SpondylArthritis international Society (ASAS). The ASAS Response Criteria (ASAS 40) is defined as an improvement in at least 40% and an absolute improvement in at least 10 units on a 0-100 scale in at least three of the following domains: Patient global assessment, Pain assessment, Function, and Inflammation (last 2 questions of BASDAI).
Week 0
Secondary Effect at 12 weeks of placebo on clinical therapeutic response: ASA40 Clinical response rates observed at 3 months in patients treated with anti-IL-17 without fiber supplementation will be recorded as a percentage.
The ASAS40 will be used to measure the percentage of patients responding positively to treatment.This tool was developed by the Assessment of SpondylArthritis international Society (ASAS). The ASAS Response Criteria (ASAS 40) is defined as an improvement in at least 40% and an absolute improvement in at least 10 units on a 0-100 scale in at least three of the following domains: Patient global assessment, Pain assessment, Function, and Inflammation (last 2 questions of BASDAI).
Week 12
Secondary Effect at 12 weeks of placebo on clinical therapeutic response: ASDAS Clinical response rates observed at 3 months in patients treated with anti-IL-17 without fiber supplementation will be recorded as a percentage. The ASDAS (Ankylosing Spondylitis Disease Activity Score) will be used to measure the percentage of patients responding positively to treatment. This tool is an index to assess disease activity in Ankylosing Spondylitis. The preferred score uses CRP (C-reactive protein) rather than ESR (erythrocyte sedimentation rate). Week 0
Secondary Effect at 12 weeks of placebo on clinical therapeutic response: ASDAS Clinical response rates observed at 3 months in patients treated with anti-IL-17 without fiber supplementation will be recorded as a percentage. The ASDAS (Ankylosing Spondylitis Disease Activity Score) will be used to measure the percentage of patients responding positively to treatment. This tool is an index to assess disease activity in Ankylosing Spondylitis. The preferred score uses CRP (C-reactive protein) rather than ESR (erythrocyte sedimentation rate). Week 12
Secondary Effect of placebo on clinical therapeutic response: GIQLI Clinical response rates observed in patients treated with anti-IL-17 without fiber supplementation will be recorded as a percentage.
Digestive symptoms will be assessed using the Gastrointestinal Quality of Life Index (GIQLI) questionnaire at Week 0 and Week 12. The GIQLI is a measure of the subjective perception of well-being by a patient, which may vary unexpectedly between diagnostic groups. The GIQLI was initiated in Germany and includes 36 items asking about symptoms, physical status, emotions, social dysfunction, and effects of medical treatment. The Questions cover the following 5 dimensions : symptoms, physical condition, emotions, social integration and medical treatment.
Week 0
Secondary Effect of placebo on clinical therapeutic response: GIQLI Clinical response rates observed at 3 months in patients treated with anti-IL-17 without fiber supplementation will be recorded as a percentage.
Digestive symptoms will be assessed using the Gastrointestinal Quality of Life Index (GIQLI) questionnaire at Week 0 and Week 12. The GIQLI is a measure of the subjective perception of well-being by a patient, which may vary unexpectedly between diagnostic groups. The GIQLI was initiated in Germany and includes 36 items asking about symptoms, physical status, emotions, social dysfunction, and effects of medical treatment. The Questions cover the following 5 dimensions : symptoms, physical condition, emotions, social integration and medical treatment.
Week 12
Secondary Tolerance of anti-IL17 intervention and treatment in the experimental group: Permeability Changes in serum concentrations of intestinal permeability markers (zonulin, claudin-3, iFABP); and endotoxemia (LBP, CD14s) will be measured by ELISA in ng/ml Month 0
Secondary Tolerance of anti-IL17 intervention and treatment in controls: Permeability Changes in serum concentrations of intestinal permeability markers (zonulin, claudin-3, iFABP); and endotoxemia (LBP, CD14s) will be measured by ELISA in ng/ml Month 3
Secondary Tolerance of anti-IL17 intervention and treatment in the experimental group The distribution and diversity of different germs will be measured by 16S RNA sequencing.
Quantitative
Month 3
Secondary Tolerance of anti-IL17 intervention and treatment in controls The distribution and diversity of different germs will be measured by 16S RNA sequencing.
Quantitative
Month 3
Secondary Presence of candida in patients in the experimental group YES/NO Month 3
Secondary Presence of candida in patients in the control group YES/NO Month 3
Secondary Tolerance of treatment in the experimental group All adverse events related or not to anti-IL17 treatment and potentially associated with the consumption of high doses of fiber (bloating, flatulence, diarrhea, abdominal pain) will be recorded Month 3
Secondary Tolerance of treatment in the control group All adverse events related or not to anti-IL17 treatment and potentially associated with the consumption of high doses of fiber (bloating, flatulence, diarrhea, abdominal pain) will be recorded Month 3
Secondary Complete blood count: Red blood cells in the experimental group Red blood cells will be measured in millions/mm3 Month 0
Secondary Complete blood count: Red blood cells in the control group Red blood cells will be measured in millions/mm3 Month 0
Secondary Complete blood count: Red blood cells in the experimental group Red blood cells will be measured in millions/mm3 Month 3
Secondary Complete blood count: Red blood cells in the control group Red blood cells will be measured in millions/mm3 Month 3
Secondary Complete blood count: White blood cells in the experimental group White blood cells will be measured in millions/mm3 Month 0
Secondary Complete blood count: White blood cells in the control group White blood cells will be measured in millions/mm3 Month 0
Secondary Complete blood count: White blood cells in the experimental group White blood cells will be measured in millions/mm3 Month 3
Secondary Complete blood count: White blood cells in the control group White blood cells will be measured in millions/mm3 Month 3
Secondary Complete blood count: Hemoglobin in the experimental group Hemoglobin will be measured in g/L Month 0
Secondary Complete blood count: Hemoglobin in the control group Hemoglobin will be measured in g/L Month 0
Secondary Complete blood count: Hemoglobin in the experimental group Hemoglobin will be measured in g/L Month 3
Secondary Complete blood count: Hemoglobin in the control group Hemoglobin will be measured in g/L Month 3
Secondary Complete blood count: Hematocrit in the experimental group Hematocrit will be measured as a % of whole blood Month 0
Secondary Complete blood count: Hematocrit in the control group Hematocrit will be measured as a % of whole blood Month 0
Secondary Complete blood count: Hematocrit in the experimental group Hematocrit will be measured as a % of whole blood Month 3
Secondary Complete blood count: Hematocrit in the control group Hematocrit will be measured as a % of whole blood Month 3
Secondary Complete blood count: Platelets in the experimental group Platelets will be measured in K/µL Month 0
Secondary Complete blood count: Platelets in the control group Platelets will be measured in K/µL Month 0
Secondary Complete blood count: Platelets in the experimental group Platelets will be measured in K/µL Month 3
Secondary Complete blood count: Platelets in the control group Platelets will be measured in K/µL Month 3
Secondary T-lymphocytes in the experimental group The phenotype of T-lymphocytes (Treg, Thelpers) will be measured as % of total white blood cells Month 0
Secondary T-lymphocytes in the control group The phenotype of T-lymphocytes (Treg, Thelpers) will be measured as % of total white blood cells Month 0
Secondary T-lymphocytes in the experimental group The phenotype of T-lymphocytes (Treg, Thelpers) will be measured as % of total white blood cells Month 3
Secondary T-lymphocytes in the control group The phenotype of T-lymphocytes (Treg, Thelpers) will be measured as % of total white blood cells Month 3
Secondary Monocytes in the experimental group Monocytes will be measured by flow cytometry (CD25, CD127, CXCR3, CCR6, CD294, CD14, CD16, TNF, IL-6) as % of total white blood cells Month 0
Secondary Monocytes in the control group Monocytes will be measured by flow cytometry (CD25, CD127, CXCR3, CCR6, CD294, CD14, CD16, TNF, IL-6) as % of total white blood cells Month 0
Secondary Monocytes in the experimental group Monocytes will be measured by flow cytometry (CD25, CD127, CXCR3, CCR6, CD294, CD14, CD16, TNF, IL-6) as % of total white blood cells Month 3
Secondary Monocytes in the control group Monocytes will be measured by flow cytometry (CD25, CD127, CXCR3, CCR6, CD294, CD14, CD16, TNF, IL-6) as % of total white blood cells Month 3
Secondary Aspartate aminotransferase (ASAT) in the experimental group Aspartate aminotransferase (or ASAT) will be measured in international units per liter Month 0
Secondary Aspartate aminotransferase (ASAT) in the experimental group Aspartate aminotransferase (or ASAT) will be measured in international units per liter Month 3
Secondary Aspartate aminotransferase (ASAT) in the control group Aspartate aminotransferase (or ASAT) will be measured in international units per liter Month 0
Secondary Aspartate aminotransferase (ASAT) in the control group Aspartate aminotransferase (or ASAT) will be measured in international units per liter Month 3
Secondary Alanine aminotransferase (ALAT) in the experimental group Alanine aminotransferase (ALAT) will be measured in international units per liter Month 0
Secondary Alanine aminotransferase (ALAT) in the experimental group Alanine aminotransferase (ALAT) will be measured in international units per liter Month 3
Secondary Alanine aminotransferase (ALAT) in the control group Alanine aminotransferase (ALAT) will be measured in international units per liter Month 0
Secondary Alanine aminotransferase (ALAT) in the control group Alanine aminotransferase (ALAT) will be measured in international units per liter Month 3
Secondary Alkaline phosphatase in the experimental group Alkaline phosphatase (ALP) will be measured in units per liter Month 0
Secondary Alkaline phosphatase in the experimental group Alkaline phosphatase (ALP) will be measured in units per liter Month 3
Secondary Alkaline phosphatase in the control group Alkaline phosphatase (ALP) will be measured in units per liter Month 0
Secondary Alkaline phosphatase in the control group Alkaline phosphatase (ALP) will be measured in units per liter Month 3
Secondary Calcium in the experimental group Calcium will be measured in mmol/L Month 0
Secondary Calcium in the experimental group Calcium will be measured in mmol/L Month 3
Secondary Calcium in the control group Calcium will be measured in mmol/L Month 0
Secondary Calcium in the control group Calcium will be measured in mmol/L Month 3
Secondary Creatinine in the experimental group Calcium will be measured in µmol/L Month 0
Secondary Creatinine in the experimental group Calcium will be measured in µmol/L Month 12
Secondary Creatinine in the control group Calcium will be measured in µmol/L Month 0
Secondary Creatinine in the control group Calcium will be measured in µmol/L Month 12
Secondary Albumin in the experimental group Albumin will be measured in g/liter Month 0
Secondary Albumin in the experimental group Albumin will be measured in g/liter Month 12
Secondary Albumin in the control group Albumin will be measured in g/liter Month 0
Secondary Albumin in the control group Albumin will be measured in g/liter Month 12
Secondary Urea in the experimental group Urea will be measured in mmol/L Month 0
Secondary Urea in the experimental group Urea will be measured in mmol/L Month 12
Secondary Urea in the control group Urea will be measured in mmol/L Month 0
Secondary Urea in the control group Urea will be measured in mmol/L Month 12
Secondary Bilirubin in the experimental group Bilirubin will be measured in µmol/L Month 0
Secondary Bilirubin in the experimental group Bilirubin will be measured in µmol/L Month 12
Secondary Bilirubin in the control group Bilirubin will be measured in µmol/L Month 0
Secondary Bilirubin in the control group Bilirubin will be measured in µmol/L Month 12
Secondary C-Reactive Protein in the experimental group C-Reactive Protein will be measured in mg/L Month 0
Secondary C-Reactive Protein in the experimental group C-Reactive Protein will be measured in mg/L Month 12
Secondary C-Reactive Protein in the control group C-Reactive Protein will be measured in mg/L Month 0
Secondary C-Reactive Protein in the control group C-Reactive Protein will be measured in mg/L Month 12
See also
  Status Clinical Trial Phase
Completed NCT05031767 - Remote Monitoring of Axial Spondyloarthritis N/A
Completed NCT05162937 - to Evaluate the Preliminary Efficacy and Safety of GR1501 Injection in Patients With Active Axial Spondyloarthritis Phase 2
Completed NCT03622658 - Efficacy and Safety of Namilumab for Moderate-to-severe Axial Spondyloarthritis Phase 2
Completed NCT03248518 - Lessening the Impact of Fatigue in Inflammatory Rheumatic Diseases N/A
Terminated NCT02437162 - A Study to Evaluate the Efficacy and Safety of Ustekinumab in the Treatment of Anti-TNFα Naive Participants With Active Radiographic Axial Spondyloarthritis Phase 3
Enrolling by invitation NCT06072859 - The Impact of Simulated Forest Immersion Therapy on Pain and Anxiety in Patients Axial Spondyloarthritis (axSpA) N/A
Completed NCT02552212 - Multicenter Study Evaluating Certolizumab Pegol Compared to Placebo in Subjects With axSpA Without X-ray Evidence of AS Phase 3
Active, not recruiting NCT02687620 - Does Immunogenicity Have an Influence on the Efficacy of Anti-TNF Therapy in Patients With AS: An Inception Cohort Study
Active, not recruiting NCT01944163 - The IMPACT of a Referral Model for Axial Spondyloarthritis in Young Patients With Chronic Low Back Pain N/A
Completed NCT00844805 - Infliximab for Treatment of Axial Spondyloarthritis (P05336 AM1) Phase 3
Terminated NCT02897115 - A Study Treating Participants With Early Axial Spondyloarthritis (axSpA) Taking an Intense Treatment Approach Versus Routine Treatment Phase 4
Completed NCT05019547 - The Turkish Version of the Inflammatory Arthritis Facilitators and Barriers to Physical Activity
Recruiting NCT03738956 - Safety and Efficacy of Tofacitinib in the Treatment of NSAID Refractory Axial Spondyloarthritis:A Clinical Trial Phase 2/Phase 3
Completed NCT04679649 - Physiotherapy of Axial Spondyloarthritis N/A
Enrolling by invitation NCT02962479 - Is the Human Microbiome Altered in Patients With Axial Spondyloarthritis? N/A
Completed NCT04485078 - Investigation of Central Sensitization Frequency and Related Factors in Axial Spondyloarthritis Patients
Completed NCT03039088 - PREDICT-SpA - French Epidemiological Study of the Evaluation of the Impact of Fibromyalgia in the TNF Alpha Treatment Effect in Axial Spondyloarthritis in Both Anti-TNF naïve and - Experienced Patients
Completed NCT04368494 - Exercise Therapy in Patients With Axial Spondyloarthritis N/A
Completed NCT03270501 - Efficacy of Golimumab in Early Axial Spondyloarthritis in Relation to Gut Inflammation Phase 3
Completed NCT03043846 - Treat to Target Trial in Axial Spondylo Arthritis : The TICOSPA (Tight Control in Spondyloarthritis)